The drug is selling because hospitals are using it in desperation
As India's economy continues to find its footing in the wake of the pandemic, the central government has renewed the Reserve Bank's Monetary Policy Committee with three fresh external voices, reaffirming the institutional machinery that guides the nation's interest rates. Around this anchor of continuity, the broader financial and corporate landscape tells a more uneven story — some sectors reaching tentatively toward recovery, others still measuring the depth of disruption. In this moment of transition, the distance between sequential rebound and year-on-year decline captures the essential tension of an economy neither fully wounded nor yet whole.
- The RBI's rate-setting body regains its full complement after a vacancy gap, with three new academic and policy minds stepping in to steer monetary decisions through an economy still scarred by Covid-19.
- Yes Bank's deposit base swells to ₹1.35 lakh crore — a 15.7% sequential rise — signaling that depositor trust, once shattered, is quietly being rebuilt brick by brick.
- Tata Motors absorbs an 11.9% year-on-year sales fall yet surges 53% sequentially, a split verdict that reveals how recovery is arriving unevenly across geographies, with China leading and domestic demand lagging.
- Biocon's itolizumab records a sevenfold sales jump after emergency Covid authorization, yet the health ministry has withheld formal protocol endorsement — leaving the drug in a commercially promising but medically ambiguous limbo.
- Dr. Reddy's Sputnik V trial faces a regulatory revision request, while Sobha's real estate sales slide 14% year-on-year, together illustrating that neither medicine nor property has yet escaped the pandemic's gravitational pull.
India's central government has appointed Ashima Goyal, Jayanth R. Varma, and Shashanka Bhide as the three new external members of the Reserve Bank's Monetary Policy Committee, filling seats vacated when the previous cohort completed their four-year terms in September. The reconstitution ensures that the body responsible for setting interest rates remains fully operational as the economy works through the pandemic's aftermath.
In banking, State Bank of India is preparing for a leadership transition, with the Banks Board Bureau recommending two internal candidates — S Janakiraman and Ashwini Kumar Tewari — for the managing director role. HDFC, the country's dominant mortgage lender, reported a recovery in individual loan disbursements during the second quarter, suggesting that confidence in the housing market is cautiously returning. Yes Bank added further cause for optimism, with its deposit base growing 15.7% sequentially to ₹1.35 lakh crore, a sign that the institution is steadily rebuilding trust after its earlier crisis.
On the corporate side, Tata Motors reported a year-on-year sales decline of 11.9%, yet the sequential rebound of 53% — driven in part by recovering demand in China — offered a more hopeful read on the direction of travel. Britannia Industries chose the moment to reward shareholders, with its board approving bonus debentures and dividends, framing the gesture as recognition of investor patience through an extraordinary period.
The pharmaceutical sector presented a study in regulatory complexity. Dr. Reddy's Laboratories was asked to revise its clinical trial protocol for the Sputnik V vaccine, a reminder that speed and rigor remain in tension. Biocon's repurposed drug itolizumab saw sales leap sevenfold following emergency Covid authorization, yet the health ministry has not included it in the official clinical management protocol — a distinction that clouds its long-term prospects despite the commercial surge.
Elsewhere, Infibeam Avenues licensed its payments and ecommerce software to Jio Platforms, deepening India's digital payments consolidation. And Sobha Ltd reported a 14% year-on-year fall in residential sales volumes, a quiet reminder that the property market's recovery remains incomplete.
The Reserve Bank of India has filled three vacancies on its Monetary Policy Committee with the appointment of Ashima Goyal, Jayanth R. Varma, and Shashanka Bhide. The move comes after the previous slate of external members completed their four-year terms in September, and it signals the continuity of India's interest-rate setting machinery as the economy navigates the pandemic's aftermath.
Across the financial sector, State Bank of India is preparing for leadership transitions. The Banks Board Bureau has recommended S Janakiraman, currently the bank's deputy managing director for finance, and Ashwini Kumar Tewari, who heads SBI Cards, as candidates for the managing director position. The recommendations suggest the institution is positioning itself for the next phase of operations as it manages the fallout from Covid-19 disruptions.
HDFC, the country's largest mortgage lender, reported signs of recovery in its individual loan business during the second quarter, indicating that lending patterns are beginning to normalize after the sharp contraction earlier in the year. The improvement suggests that borrowers and lenders alike are regaining confidence in the housing market.
Yes Bank, meanwhile, has grown its deposit base to ₹1.35 lakh crore, reflecting sequential growth of 15.7% in liabilities according to provisional numbers the bank released. The expansion points to renewed depositor confidence in the institution, which had faced severe stress in the prior year.
Tata Motors, the automotive manufacturer owned by the Tata Group, reported a year-on-year sales decline of 11.9%, with unit sales falling to 113,569 vehicles. The drop reflects the lingering impact of Covid-related production and demand disruptions. However, the company saw a sharp sequential rebound of 53% as demand recovered, particularly in China, suggesting that global markets are stabilizing faster than domestic ones.
Britannia Industries, a major player in bakery and dairy products, announced that its board has approved the issuance of bonus debentures and dividend payments to shareholders. The company framed the decision as a way to reward investors during what it described as unprecedented and difficult times caused by the coronavirus crisis.
In the pharmaceutical space, Dr. Reddy's Laboratories faces a procedural hurdle with its Covid-19 vaccine development. An expert panel at the Central Drugs Standard Control Organisation has asked the company to revise its protocol for conducting phase 2 and phase 3 human clinical trials of Russia's Sputnik V vaccine in India. The request suggests the regulatory process remains rigorous even as the country races to expand vaccine options.
Biocon's experience with its repurposed psoriasis drug itolizumab illustrates the complexity of emergency authorization during a health crisis. Sales of the drug jumped sevenfold after it received emergency use authorization for Covid-19 treatment. Yet the drug remains outside the health ministry's clinical management protocol for Covid-19, meaning the government has not formally endorsed it as an effective treatment—a gap that may limit its uptake despite the commercial momentum.
Infibeam Avenues, the parent company of payment gateway CCAvenue, has licensed its ecommerce and payment software to Jio Platforms, signaling consolidation in India's digital payments infrastructure. The Gandhinagar-based company is positioning itself as a technology provider to one of the country's largest digital platforms. Meanwhile, Sobha Ltd, a Bengaluru-based real estate developer, reported that sales fell 14% year-on-year to 8.91 lakh square feet, with the value of sales declining 5.4% to ₹530.9 crore, reflecting the continued weakness in the residential property market.
Notable Quotes
Individual loan business has seen improvement in the second quarter, a sign that business is reverting to pre-covid levels— HDFC
The Hearth Conversation Another angle on the story
Why does the RBI's appointment of three new committee members matter to someone watching the stock market?
Because the Monetary Policy Committee sets interest rates, and interest rates touch everything—what banks charge borrowers, what savers earn, how expensive it is for companies to invest. New members signal whether policy will shift or stay steady. In this case, continuity matters because the economy is still fragile.
I notice HDFC and Yes Bank both show recovery signals. Are they in the same position?
Not quite. HDFC is a mortgage lender seeing demand return in housing loans—a sign of consumer confidence. Yes Bank is rebuilding deposits after a crisis. One is growing; the other is stabilizing. Both are positive, but they're different stories.
Tata Motors dropped 11.9% year-on-year but jumped 53% sequentially. How do you read that?
It's a tale of two markets. Domestically, Covid still has the auto sector in a grip. But globally, especially in China, demand is snapping back. The company is caught between a struggling home market and recovering export markets.
What strikes you about Biocon's drug sales jumping sevenfold?
The paradox. The drug is selling because hospitals and doctors are using it in desperation. But without government endorsement, it's not official policy. That gap between what's happening on the ground and what's officially sanctioned is the real story.
Is real estate in trouble?
Sobha's numbers suggest the sector hasn't found its footing yet. Housing demand is fragile. People are uncertain about jobs and income. Until that changes, developers will keep struggling.